Cargando…

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial

Non-steroidal anti-inflammatory drugs (NSAIDs), especially aspirin, have been associated with lowered cancer incidence and mortality. We examined overall cancer mortality and mortality from specific cancer sites among the 80,144 men in the Finnish Prostate Cancer Screening Trial. Information on pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veitonmäki, Thea, Murtola, Teemu J., Talala, Kirsi, Taari, Kimmo, Tammela, Teuvo, Auvinen, Anssi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839624/ https://www.ncbi.nlm.nih.gov/pubmed/27100876 http://dx.doi.org/10.1371/journal.pone.0153413

Ejemplares similares

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study
por: Peltomaa, A. I., et al.
Publicado: (2021)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
por: Rannikko, Antti, et al.
Publicado: (2022)

Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them
por: Siltari, Aino, et al.
Publicado: (2021)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study
por: Hietikko, Ronja, et al.
Publicado: (2020)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

European randomized study of prostate cancer screening: first-year results of the Finnish trial
por: Määttänen, L, et al.
Publicado: (1999)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families
por: Fischer, Daniel, et al.
Publicado: (2015)

PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
por: Pakkanen, Sanna, et al.
Publicado: (2009)

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
por: Nätkin, Reetta, et al.
Publicado: (2023)

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
por: Murtola, Teemu J., et al.
Publicado: (2012)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

Prostate cancer screening: what can we learn from randomised trials?
por: Auvinen, Anssi
Publicado: (2018)

Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients—A Nationwide Cohort Study
por: Santala, Eerik E. E., et al.
Publicado: (2021)

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases
por: Sattari, Mina, et al.
Publicado: (2023)

Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis
por: Chen, Li-Sheng, et al.
Publicado: (2014)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jjtq4ma095vnf18duvjv5hjh11